Clalit: Pfizer vaccine relieves symptomatic infections by 94%.

The Clalit Health Services Research Institute in Israel has published its first research paper on the effectiveness of COVID-19 vaccines and their effect in preventing infection and morbidity in all age groups. Clalit, the largest health maintenance organization in Israel (HMO), analyzed data from 1.2 million members – 600,000 members who received the Pfizer vaccination and 600,000 members with the same picture who had not been vaccinated, and the research found that there is a 94% reduction in cases of symptomatic infection among those who They were vaccinated, and a 92% decrease in the rate of those who became seriously ill with Covid-19 out of 600,000 who were vaccinated, compared to the 600,000 who were not vaccinated. No vaccination. Efficacy was seen in all age groups, including those over 70, who were only represented in a limited group in Pfizer’s clinical trial. Related articles Gapz at work: vaccinating Israelis at work Israeli vaccination leads to losing momentum Israeli laboratory: The vaccine appears to interrupt the transmission of the Covid virus. From seven or more days after the second dose of the vaccine. The Clalit researchers were able to say with high confidence that the efficacy against severe Covid one week after the second Pfizer dose was between 91% and 99%. Of the 600,000 in each group – vaccinated and unvaccinated – 430,000 were between the ages of 16-59 and 170,000 were 60+. Each group was carefully matched for age, risk of serious infection, underlying health conditions and general health. Professor Ran Palser, Head of the Clalit Health Services Innovation Office and Head of the Clalit Research Institute, said, “Together with our colleagues at Harvard University, we ran a series of tests to validate the results and found in an unambiguous way that the Pfizer vaccine against Covid-19 was most effective in In real life, a week after the second dose, just as the clinical research found, he added: “Moreover, the trend that we identify after additional weeks after the second dose greatly increases the effectiveness of the vaccination measure. In fact, in terms of 14 and more days after the second dose, in initial tests, we determine a higher efficacy in preventing symptoms and severe disease among those vaccinated for each age. We will soon also be able to provide an accurate assessment on this, using the same method, and we expect efficacy data to be higher. Posted by Globes, Israel business news – en.globes.co.il – on February 14, 2021 © Copyright Globes Publisher Itonut (1983) Ltd. 2021